← brief for 2026-08-12 · Slowing decline

NephJC Short: When BAFF Meets APRIL: Telitacicept in IgA Nephropathy (TELIGAN trial) — NephJC

Key takeaways

A phase 3 trial in China called TELIGAN tested telitacicept, a drug that calms the immune system, in adults with IgA nephropathy, a kidney disease driven by the immune system. This early look, at about 9 months (39 weeks), found less protein in the urine, which is a sign of less kidney damage. Protein in the urine is a stand-in marker, not a final outcome, so longer follow-up is needed to know if it truly protects kidney function.

Source

Page · Forager · 2026-08-13
https://www.nephjc.com/news/2026/short/telitacicept7526